



TO THE NATIONAL SECURITIES MARKET COMMISSION (CNMV)

Madrid, 15 December 2022

In compliance with reporting obligations provided for in article 227 of the Spanish Securities Market Law (*Ley de Mercado de Valores*), Laboratorios Farmacéuticos Rovi, S.A. (hereinafter, “**ROVI**” or the “**Company**”) hereby notifies the National Securities Market Commission (“**CNMV**”) of the following

OTHER RELEVANT INFORMATION

The Board of Directors of the Company held yesterday has adopted, among others, the following resolutions:

- (i) To accept the resignation as director and as member of the Audit Committee and the Nomination and Compensation Committee submitted by Mr. José Fernando de Almansa with effect from 14 December 2022. The reason for this resignation lies in Mr. Almansa’s intention to enable ROVI to comply in 2022 with the corporate governance recommendation on diversity in the composition of the Board of Directors, enabling the Company to appoint a female independent director to fill the vacancy left, also considering the proximity of the expiry of his term of office.

The Board of Directors thanks Mr. Almansa for his dedication and invaluable contribution to the development and growth of ROVI since his appointment as independent director in 2015. Furthermore, in order to be able to continue to rely on his experience and expertise, particularly in the international markets in which ROVI operates, the Company has decided to appoint Mr. Almansa as Chairman of the Advisory Committee, the formation of which is reported below.

- (ii) To appoint by cooptation Ms. Teresa Corzo Santamaría as independent non-executive director of the Company, at the proposal of the Nomination and Compensation Committee.

Ms. Corzo Santamaría has likewise been appointed as member of the Audit Committee and the Nomination and Compensation Committee, replacing Mr. José Fernando de Almansa.

Ms. Fátima Báñez García has been appointed as Chairman of the Nomination and Compensation Committee.

Ms. Corzo Santamaría’s professional and biographical profile can be found on the Company’s corporate webpage (www.rovi.es).

With this addition to the Board, ROVI achieves the objective set out in recommendation 15 of the CNMV’s Good Governance Code of Listed Companies for 2022 regarding the promotion of gender diversity on the Board of Directors, insofar as the number of female directors represents 43% of the members of the Board of Directors (three out of seven) and also reinforces the knowledge and expertise within the Board of Directors with Ms. Teresa Corzo’s experience in risk management, auditing and finance.



(iii) Pursuant to article 12.2 of the Regulations of the Board of Directors, and following a favourable report from the Nomination and Compensation Committee, to set up an Advisory Committee, as a permanent internal body, of an informative and consultative nature, without executive functions, and with information and advisory powers within its scope of action. ROVI's Advisory Committee will provide strategic advice to the Board of Directors, to its Committees and to the senior management of the Company, in relation to the design, development and, where appropriate, implementation of the Company's business strategy. The Advisory Committee will initially be composed of Mr. José Fernando de Almansa, who will serve as Chairman, and of Mr. Gabriel Municio Ollero, in addition to other professionals of recognised prestige and experience who may foreseeably join the Committee.

Mr. Gabriel Núñez Fernández will serve as non-member secretary of the Advisory Committee.

Mr. Juan López-Belmonte Encina
Chairman of the Board of Directors and Chief Executive Officer
Laboratorios Farmacéuticos ROVI, S.A.